patented technology to grow and expand adult Stem Cells

Adult stem cell development company commencing clinical trials applicable to estimated $30 billion degenerative disease market place

Free
Message: Is this good or not good?

"If this mgmt has a plan and can attract some serious investors it may be a go."

You said it all billw - management has to have a plan. R/S have a 75% failure rate. Pluristem must either issue BIG news or BIG institutional investors - preferably both or the stock will never make it. They will be trying to paddle upstream in a very swift river - let's hope they have a powerful motor to attach to the boat.

I hope the tech makes for more than just financial reasons - I'm sure we all have the same sentiment.

Share
New Message
Please login to post a reply